After listening to the RBC presentation and reading the Getinge PR recently, I doubt anyone could say the business fundamentals of TSO3 is worse now vs. when the preception on Jan25 when the interim deal PR came out:
- Getinge relationship sounds more solid: RR explained that TSO3 is only marketing to hospitals not targeted by Getinge, and the very complimentary Getinge PR showed us the working relationship is sound and low temperature sterilization is a key strategic market for them
- We also got more evidence of how VP4 performs in real life, and how it is truly a next-gen product: ability to do scopes, lower costs through higher load/throughput/mix load, lower operator mistakes. The robotic arm piece of news is significant as well
- FDA: now everyone knows sterility is never an issue, but compatibility. It all comes down to what the labeling will look like, and how often hospitals will need to inspect their scopes. For me, this is a matter of when, not if.
